AFT Pharmaceuticals (ASX:AFP) Cyclically Adjusted Revenue per Share: A$1.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
90 GF Score
Price A$3.19
GF Value A$3.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Cyclically Adjusted Revenue per Share?

AFT Pharmaceuticals ASX:AFP 90 Cyclically Adjusted Revenue per Share is A$1.25 as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AFT Pharmaceuticals's adjusted revenue per share data for the fiscal year that ended in Mar. 2026 was A$1.996. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is A$1.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AFT Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-14), AFT Pharmaceuticals's current stock price is A$ 3.19. AFT Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar. 2026 was A$1.25. AFT Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.55.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of AFT Pharmaceuticals was 2.55. The lowest was 1.63. And the median was 2.15.


AFT Pharmaceuticals  (ASX:AFP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AFT Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.19/1.25
=2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of AFT Pharmaceuticals was 2.55. The lowest was 1.63. And the median was 2.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AFT Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


AFT Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.34 1.25

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.34 0.00 1.25

ASX:AFP vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AFT Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


ASX:AFP
90GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AFT Pharmaceuticals's adjusted Revenue per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.996/136.8867*136.8867
=1.996

Current CPI (Mar. 2026) = 136.8867.

AFT Pharmaceuticals Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 0.655 102.231 0.877
201803 0.768 103.355 1.017
201903 0.844 104.889 1.101
202003 1.057 107.547 1.345
202103 1.014 109.182 1.271
202203 1.155 116.747 1.354
202303 1.382 124.517 1.519
202403 1.716 129.526 1.814
202503 1.781 132.798 1.836
202603 1.996 136.887 1.996

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of A$1.25 mean?
AFT Pharmaceuticals (ASX:AFP) has a Cyclically Adjusted Revenue per Share of A$1.25 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
AFT Pharmaceuticals' current Cyclically Adjusted Revenue per Share is A$1.25. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
AFT Pharmaceuticals' Cyclically Adjusted Revenue per Share of A$1.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Cyclically Adjusted Revenue per Share is A$1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is A$1.25. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Cyclically Adjusted Revenue per Share is A$1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for ASX:AFP:

  • Cyclically Adjusted Revenue per Share: A$1.25
  • GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score

Get the complete analysis for ASX:AFP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.19
Price
A$3.39
GF Value